CO5261573A1 - Derivados de benzoxa y bezotiazol, compuesto y composicion farmaceutica que los contiene y proceso para la preparacion de la mencionada composicion - Google Patents

Derivados de benzoxa y bezotiazol, compuesto y composicion farmaceutica que los contiene y proceso para la preparacion de la mencionada composicion

Info

Publication number
CO5261573A1
CO5261573A1 CO00083906A CO00083906A CO5261573A1 CO 5261573 A1 CO5261573 A1 CO 5261573A1 CO 00083906 A CO00083906 A CO 00083906A CO 00083906 A CO00083906 A CO 00083906A CO 5261573 A1 CO5261573 A1 CO 5261573A1
Authority
CO
Colombia
Prior art keywords
benzoxa
bezotiazol
derivatives
compound
preparation
Prior art date
Application number
CO00083906A
Other languages
English (en)
Inventor
Andreas Billich
Erwin Paul Schreiner
Barbara Wolff-Winisk
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9927439.1A external-priority patent/GB9927439D0/en
Priority claimed from GB0007511A external-priority patent/GB0007511D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO5261573A1 publication Critical patent/CO5261573A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

La presente invención se relaciona con una clase de benzoxa- y benzotiazoles sustituidos en la parte de heterociclilo de la estructura del anillo, y que llevan un grupo éster de ácido sulfámico.Poseen actividad farmacológica interesante.Se pueden preparar mediante la sulfamoilación de un compuesto correspondiente que lleve un grupo hidroxilo, o mediante N-sustitución.Se indican para utilizarse como inhibidores de sulfatasa de esteroide en la prevención y el tratamiento de enfermedades que respondan a la inhibición de sulfatasa de esteroide, tales como acné.<EMI FILE="00083906_1" ID="1" IMF=JPEG >
CO00083906A 1999-11-19 2000-11-03 Derivados de benzoxa y bezotiazol, compuesto y composicion farmaceutica que los contiene y proceso para la preparacion de la mencionada composicion CO5261573A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9927439.1A GB9927439D0 (en) 1999-11-19 1999-11-19 Organic compounds
GB0007511A GB0007511D0 (en) 2000-03-28 2000-03-28 Organic compounds

Publications (1)

Publication Number Publication Date
CO5261573A1 true CO5261573A1 (es) 2003-03-31

Family

ID=26243976

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00083906A CO5261573A1 (es) 1999-11-19 2000-11-03 Derivados de benzoxa y bezotiazol, compuesto y composicion farmaceutica que los contiene y proceso para la preparacion de la mencionada composicion

Country Status (15)

Country Link
US (1) US6716865B1 (es)
EP (1) EP1230227B1 (es)
JP (1) JP2003514806A (es)
AR (1) AR026504A1 (es)
AT (1) ATE269853T1 (es)
AU (1) AU1857701A (es)
CO (1) CO5261573A1 (es)
DE (1) DE60011801T2 (es)
DK (1) DK1230227T3 (es)
ES (1) ES2223620T3 (es)
HK (1) HK1049329B (es)
PE (1) PE20011012A1 (es)
PT (1) PT1230227E (es)
TR (1) TR200402432T4 (es)
WO (1) WO2001036398A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20040693A1 (es) * 2002-11-14 2004-11-23 Novartis Ag N-sulfonilaminotiazol como mediadores de la sulfatasa de esteroides
DE10260955A1 (de) * 2002-12-20 2004-07-08 Henkel Kgaa Verwendung von Steroidsulfatase-Inhibitoren zur Verminderung von Haarausfall
ES2655028T3 (es) 2007-08-02 2018-02-16 Millennium Pharmaceuticals, Inc. Proceso para la síntesis de inhibidores de enzima de activación de E1
US20100204146A1 (en) 2007-09-17 2010-08-12 Preglem S.A. Treatment of Oestrogen Dependant Conditions in Pre-menopausal Women
CN104926730B (zh) * 2014-03-21 2017-07-21 中国科学院武汉岩土力学研究所 一种松香基咪唑啉类化合物及其合成方法和应用
CA3036245C (en) * 2016-09-13 2021-07-20 Arbutus Biopharma Corporation Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2868800A (en) 1954-10-13 1959-01-13 Upjohn Co 6-ethoxybenzothiazole-2-sulfonamide
US4472418A (en) * 1983-04-22 1984-09-18 Merck & Co., Inc. Benzothiazolesulfonamide derivatives for the topical treatment of elevated intraocular pressure
FI91869C (fi) 1987-03-18 1994-08-25 Tanabe Seiyaku Co Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi
US5273993A (en) 1989-06-12 1993-12-28 A. H. Robins Company, Incorporated Compounds having one or more aminosulfonyloxy radicals useful as pharmaceuticals
US5194446A (en) 1989-06-12 1993-03-16 A. H. Robins Company, Incorporated Compounds having one or more aminosulfaonyloxy radicals useful as pharmaceuticals
PT94305B (pt) * 1989-06-12 1997-02-28 Robins Co Inc A H Processo para a preparacao de compostos tendo um ou mais radicais aminossulfoniloxi uteis como produtos farmaceuticos
US5192785A (en) 1989-09-03 1993-03-09 A. H. Robins Company, Incorporated Sulfamates as antiglaucoma agents
SG64322A1 (en) 1991-05-10 1999-04-27 Rhone Poulenc Rorer Int Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
AU3221993A (en) 1991-11-27 1993-06-28 Phanos Technologies, Inc. Compounds, compositions and methods for binding bio-affecting substances to surface membranes of bio-particles
EP0664792B1 (en) 1992-10-14 2000-01-05 Merck & Co. Inc. Fibrinogen receptor antagonists
WO1996011917A1 (en) 1994-10-12 1996-04-25 Euro-Celtique, S.A. Novel benzoxazoles
US6169085B1 (en) * 1995-03-10 2001-01-02 G. D. Searle & Company Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
US5677321A (en) 1996-02-29 1997-10-14 Synaptic Pharmaceutical Corporation 5- and 6-(2-imidazolin-2-ylamino) and -(2-thiazolin-2-ylamino)-benzothiazoles as alpha-2 adrenergic ligands
US5709845A (en) 1996-05-13 1998-01-20 Rajagopalan; Raghavan Tricyclic functional dyes for contrast enhancement in optical imaging
DE19653647A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
JPH10237053A (ja) 1997-02-24 1998-09-08 Sumitomo Chem Co Ltd ベンゾチアゾール類の製造方法
US6140051A (en) 1997-07-21 2000-10-31 Promega Biosciences, Inc. Fluorescent dibenzazole derivatives and methods related thereto
GB2331988B (en) * 1997-12-04 2003-04-16 Imperial College Polycyclic sulphamate inhibitors or oestrone sulphatase
GB9807779D0 (en) 1998-04-09 1998-06-10 Ciba Geigy Ag Organic compounds
ATE268327T1 (de) 1998-06-18 2004-06-15 Novartis Pharma Gmbh Benzazol-verbindungen und ihre verwendung

Also Published As

Publication number Publication date
AR026504A1 (es) 2003-02-12
ES2223620T3 (es) 2005-03-01
EP1230227B1 (en) 2004-06-23
DE60011801D1 (de) 2004-07-29
JP2003514806A (ja) 2003-04-22
EP1230227A1 (en) 2002-08-14
DK1230227T3 (da) 2004-08-16
ATE269853T1 (de) 2004-07-15
PT1230227E (pt) 2004-10-29
TR200402432T4 (tr) 2004-12-21
AU1857701A (en) 2001-05-30
HK1049329A1 (en) 2003-05-09
WO2001036398A1 (en) 2001-05-25
US6716865B1 (en) 2004-04-06
PE20011012A1 (es) 2001-10-02
HK1049329B (zh) 2005-03-24
DE60011801T2 (de) 2005-07-14

Similar Documents

Publication Publication Date Title
CL2004001182A1 (es) Composicion farmaceutica que comprende a una microparticula de liberacion sostenida la que contiene a un derivado de 1,2 benzazol; procedimiento de preparacion de la microparticula; util como broncodilatador, antipsicoticos y en otros problemas del s
ATE323473T1 (de) Pharmazeutische zusammensetzungen enthaltend resveratrol und verwendungen davon
SE9704870D0 (sv) New pharmaceutical formulation I
AP1666A (en) Quinolinone derivatives as tyrosine kinase inhibitors.
BR0009200A (pt) Compostos e composições para o tratamento dedoenças associada com disfunção imune
EA200100870A1 (ru) Композиции-ингибиторы циклооксигеназы-2 с быстро наступающим терапевтическим действием
AR033548A1 (es) Composicion farmaceutica que comprende un inhibidor de lipasa, un procedimiento para su preparacion, equipo transportable a modo de &#39;&#39;kit&#39;&#39;, el uso de dicha composicion en la fabricacion de medicamentos, un inhibidor de lipasa y un secuestrante de acidos biliares
IS2354B (is) Lyfjasamsetning sem mögulegt er að hleypa
SE9804000D0 (sv) New composition of matter
DE60029799D1 (de) Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe
ES2733044T1 (es) Composición farmacéutica que contiene oxicodona y naloxona
CR9704A (es) Composicion farmaceutica de liberacion modificada, proceso de preparacion y metodo para emplear la misma.
AR008927A1 (es) Una composicion farmaceutica que comprende una sustancia medicinalmente activa insoluble en agua con propiedades mejoradas de disolucion, absorcion, etc., y el procedimiento para prepararla
PT921787E (pt) Regime de administracao de inibidores de atpase de h&#39;,k&#39;
AR007021A1 (es) Derivados de 3-descladinosa-2,3-anhidroeritromicina, procedimientos para su preparacion, compuestos para su exclusivo uso en dichos procedimientosy procedimiento para su preparacion, una composicion farmaceutica para tratar infecciones bacterianas y el uso de estos compuestos para preparar medicamentos
DK0912185T3 (da) Nye farmaceutiske sammensætninger indeholdende steroidnitratesterderivater, der kan anvendes som antiinflammatoriske lægemidler
CO5261573A1 (es) Derivados de benzoxa y bezotiazol, compuesto y composicion farmaceutica que los contiene y proceso para la preparacion de la mencionada composicion
BR0008302A (pt) Uso de um derivado de benzaldeìdo, derivado de benzaldeìdo, composição farmacêutica, e, processo para a fabricação da mesma
AR026655A1 (es) Nuevos esteroides con actividad androgenica y su uso como antinconceptivos masculinos y para tratar la insuficiencia androgenica
EE9800233A (et) Benso[c]kinolisiini derivaadid, nende valmistamine ja kasutamine 5a-reduktaasi inhibiitoritena
BR0016601A (pt) Composição farmacêutica para a prevenção ou tratamento da ejaculação precoce e/ou da hipersensibilidade da estimulação sexual
HUP0203045A2 (hu) Epesavval képezett 4-benzil-amino-kinolin konjugátumok és hetero-analógjai, valamint eljárás a vegyületek előállítására és a vegyületeket tartalmazó gyógyászati készítmények, és ezek alkalmazása
CO4750645A1 (es) Metodo de preparacion de granulos que incorporan un medica- mento para uso farmaceutico
ECSP003773A (es) Benzoxa y benzotiazoles
AR017455A1 (es) Composiciones farmaceuticas que comprenden (1s,4r)-cis-4-[2-amino-6-ciclopropilamino)-9h-purin-9-ilo]-2-ciclopenten-1-metanol, un quelante de metal y un agente edulcorante

Legal Events

Date Code Title Description
FA Application withdrawn